Phase 3 Trial Data Shows Positive Results for Oral Treatment of Acromegaly

April 28, 2021

Data presented last month at ENDO 2021 from Phase 3 of the MPOWERED study showed that oral octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. In addition, oral octreotide capsules met the pre-specified non-inferiority margin compared to long-acting iSRLs in maintenance of […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Researchers Determine Best Predictors of Acromegaly Remission Following Transsphenoidal Surgery

Progression of Acromegalic Arthropathy Observed in Long-Term Study→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today